Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 18, 2021 | Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 2 Study of AP-101 for the Treatment of ALS | SCHLIEREN, Switzerland, Nov. 18, 2021 /PRNewswire/ -- AL-S Pharma AG, a biotech company jointly founded by Neurimmune and TVM Capital Life Science, announced today enrollment of the first patient in a multicenter, placebo-controlled Phase 2... |
| Dec 7, 2016 | Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with ALS | Schlieren, Switzerland, and Munich, Germany, December 07, 2016 / B3C newswire / — Neurimmune and TVM Capital Life Science’s latest fund, TVM Life Science Ventures VII, today announced their investment in AL-S Pharma AG, a company based in S... |
Reviews 0
FAQ about AL
What has the press written about AL?
Parsers VC has collected 3 articles mentioning AL, among them “Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 2 Study of AP-101 for the Treatment of ALS” (Nov 18, 2021) and “Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with ALS” (Dec 7, 2016).
Is AL still active?
Yes, AL is active; its latest activity on Parsers VC dates from Oct 15, 2026.